Literature DB >> 16545818

Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking.

Qi Wei1, Peter A Doris, Martin V Pollizotto, Eric Boerwinkle, David R Jacobs, David S Siscovick, Myriam Fornage.   

Abstract

Soluble epoxide hydrolase (EPHX2) catalyses the degradation of the vasoactive and anti-inflammatory epoxyeicosatrienoic acids and may play a role in the pathophysiology of atherosclerosis. 1337 African-Americans and 1645 Whites from the CARDIA study were genotyped for 22 and 15 EPHX2 single nucleotide polymorphisms (SNPs), respectively, to examine the associations of common EPHX2 haplotypes and genotypes with presence of coronary artery calcified plaque (CAC). The potential influence of cigarette smoking, which increases EPHX2 gene expression, on these associations was also assessed. In African-Americans, a common haplotype uniquely tagged by the R287Q polymorphism was associated with significantly greater risk for CAC (OR=1.7; 95% CI=1.04-3.0). In Whites, a common haplotype uniquely tagged by a polymorphism in Intron 11 of the gene was associated with significantly greater risk for CAC (OR=1.3; 95% CI=1.02-1.6). These haplotype-tagging polymorphisms also showed significant associations with CAC in individual SNP analyses, and these relationships were significantly modified by smoking. This detailed investigation of the association of EPHX2 genetic variation with CAC supports EPHX2's emerging role as a risk factor for atherosclerosis, whose effects are influenced by smoking.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545818     DOI: 10.1016/j.atherosclerosis.2006.02.021

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  34 in total

Review 1.  Genetic and epigenetic regulation of human aging and longevity.

Authors:  Brian J Morris; Bradley J Willcox; Timothy A Donlon
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-09-01       Impact factor: 5.187

Review 2.  Therapeutic approaches to drug targets in atherosclerosis.

Authors:  Prasad G Jamkhande; Prakash G Chandak; Shashikant C Dhawale; Sonal R Barde; Priti S Tidke; Ram S Sakhare
Journal:  Saudi Pharm J       Date:  2013-11-05       Impact factor: 4.330

Review 3.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

4.  Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling.

Authors:  Matthias J Merkel; Lijuan Liu; Zhiping Cao; William Packwood; Jennifer Young; Nabil J Alkayed; Donna M Van Winkle
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-11       Impact factor: 4.733

5.  Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent.

Authors:  Jeffrey J Iliff; Nabil J Alkayed
Journal:  Future Neurol       Date:  2009-03-01

Review 6.  Soluble epoxide hydrolase in atherosclerosis.

Authors:  Yi-Xin Jim Wang; Arzu Ulu; Le-Ning Zhang; Bruce Hammock
Journal:  Curr Atheroscler Rep       Date:  2010-05       Impact factor: 5.113

Review 7.  Soluble epoxide hydrolase: gene structure, expression and deletion.

Authors:  Todd R Harris; Bruce D Hammock
Journal:  Gene       Date:  2013-05-20       Impact factor: 3.688

8.  Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study.

Authors:  Kathryn P Burdon; Allison B Lehtinen; Carl D Langefeld; J Jeffrey Carr; Stephen S Rich; Barry I Freedman; David Herrington; Donald W Bowden
Journal:  Diab Vasc Dis Res       Date:  2008-06       Impact factor: 3.291

9.  Nutrigenomic analysis of diet-gene interactions on functional supplements for weight management.

Authors:  Francis C Lau; Manashi Bagchi; Chandan Sen; Sashwati Roy; Debasis Bagchi
Journal:  Curr Genomics       Date:  2008-06       Impact factor: 2.236

10.  Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention.

Authors:  Silke Kullmann; Priska Binner; Kirsten Rackebrandt; Andreas Huge; Georg Haltern; Mark Lankisch; Reiner Füth; Eberhard von Hodenberg; Hans-Peter Bestehorn; Thomas Scheffold
Journal:  BMC Cardiovasc Disord       Date:  2009-10-08       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.